Furthermore, SCD1 inhibitors enhance CCL4 production by cancer cells through the inactivation of Wnt/β-catenin signaling, which promotes recruitment of DCs into the tumors, and increases CD8+ T cells infiltration and activation [198]. The gene discussed is CD8A; the disease is cancer.